Amplyx Pharmaceuticals is developing novel, broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The company's lead compound, APX001, will enter clinical development in 2016 and has shown broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus, as well as high potency against rare, difficult-to-treat molds. Amplyx has raised $42.5 million in venture capital and received more than $10 million in grants from the National Institutes of Health to supports its drug discovery and development efforts. The company's research operations are located at Johnson & Johnson Innovation, JLABS in San Diego, Calif.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/11/15 | $40,500,000 | Series B |
BioMed Ventures RiverVest Venture Partners | undisclosed |
| 02/09/16 | $8,700,000 | Series B |
3x5 Partners | undisclosed |
| 08/02/17 | $67,000,000 | Series C |
3x5 Partners Arix Bioscience BioMed Ventures Lundbeckfond Ventures Pappas Ventures RiverVest Venture Partners Sofinnova Ventures  | undisclosed |
| 05/19/20 | $53,000,000 | Series C Extension |
3x5 Partners Adage Capital Management Arix Bioscience BioMed Ventures Lundbeckfonden Ventures New Enterprise Associates Pappas Capital Pfizer Venture Investments RiverVest Venture Partners Sofinnova Ventures | undisclosed |
